Androgen pathway resistance in prostate cancer and therapeutic implications
about
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate CancerEdelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor ActivityExploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.Synthesis and basic evaluation of 7α-(3-[18F]fluoropropyl)-testosterone and 7α-(3-[18F]fluoropropyl)-dihydrotestosterone.Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study.Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.Implications of Bcl-2 and its interplay with other molecules and signaling pathways in prostate cancer progression.Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.Molecular and cellular mechanisms of castration resistant prostate cancer.Analysis of differentially expressed genes, clinical value and biological pathways in prostate cancer.
P2860
Q26751237-30CDE47C-AC6D-4B77-9E12-CEDBA3FA3871Q37066598-D22E34E8-FF71-463A-BF19-89DFE6ADD4AEQ38813222-84D7B153-7A06-4147-A135-8D641B1DE3D9Q38929688-CCE4D4E4-D56C-4492-938F-8A801D5E76F6Q39344206-5CFD3943-B861-45EC-B67A-2D10D1583F62Q39487974-E115F179-17AC-4A53-AF4F-41AC219B81E9Q40355149-4B96FBB2-864B-4ED5-AA4E-E4BD58C85FE6Q40608123-01DE1244-DE70-41CE-90E0-EAE13E7F164DQ47231171-2C502D52-CF2E-40A2-8CB2-81B005736C6BQ47941645-BF2D7194-2BDD-4291-BCFD-4A11ED67E674Q48333900-007B24B6-720E-48F8-88BA-BDF3F31D76AEQ52608488-EC1F07C0-16C0-4391-835C-71CAE7DFE296Q55004153-0C2BE379-1B8B-40ED-9175-90C33F6428C7
P2860
Androgen pathway resistance in prostate cancer and therapeutic implications
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Androgen pathway resistance in prostate cancer and therapeutic implications
@ast
Androgen pathway resistance in prostate cancer and therapeutic implications
@en
type
label
Androgen pathway resistance in prostate cancer and therapeutic implications
@ast
Androgen pathway resistance in prostate cancer and therapeutic implications
@en
prefLabel
Androgen pathway resistance in prostate cancer and therapeutic implications
@ast
Androgen pathway resistance in prostate cancer and therapeutic implications
@en
P2860
P1476
Androgen pathway resistance in prostate cancer and therapeutic implications
@en
P2093
Benjamin L Maughan
Emmanuel S Antonarakis
P2860
P304
P356
10.1517/14656566.2015.1055249
P407
P577
2015-06-12T00:00:00Z